• If you are having problems logging in please use the Contact Us in the lower right hand corner of the forum page for assistance.

vCJD risk from transfusion for 23 known recipients HIGH

flounder

Well-known member
----- Original Message -----
From: "Terry S. Singeltary Sr." <[email protected]>
To: <[email protected]>
Sent: Thursday, December 07, 2006 9:03 PM
Subject: Clinical presentation and pre-mortem diagnosis of variant
Creutzfeldt-Jakob disease associated with blood transfusion: a case report


##################### Bovine Spongiform Encephalopathy
#####################

The Lancet 2006; 368:2061-2067

DOI:10.1016/S0140-6736(06)69835-8

Articles

Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob
disease associated with blood transfusion: a case report

Stephen J Wroe FRCP a b, Suvankar Pal MRCP a b, Durrenajaf Siddique MRCP a
b, Harpreet Hyare FRCR a b, Rebecca Macfarlane MRCS a b, Susan Joiner MSc b,
Jacqueline M Linehan BSc b, Sebastian Brandner MRCPath b, Jonathan DF
Wadsworth PhD b, Patricia Hewitt FRCPath c and Prof John Collinge FRS a b

Summary
Background
Concerns have been raised that variant Creutzfeldt-Jakob disease (vCJD)
might be transmissible by blood transfusion. Two cases of prion infection in
a group of known recipients of transfusion from donors who subsequently
developed vCJD were identified post-mortem and reported in 2004. Another
patient from this at-risk group developed neurological signs and was
referred to the National Prion Clinic.

Methods
The patient was admitted for investigation and details of blood transfusion
history were obtained from the National Blood Service and Health Protection
Agency; after diagnosis of vCJD, the patient was enrolled into the MRC
PRION-1 trial. When the patient died, brain and tonsil tissue were obtained
at autopsy and assessed for the presence of disease-related PrP by
immunoblotting and immunohistochemistry.

Findings
A clinical diagnosis of probable vCJD was made; tonsil biopsy was not done.
The patient received experimental therapy with quinacrine, but deteriorated
and died after a clinical course typical of vCJD. Autopsy confirmed the
diagnosis and showed prion infection of the tonsils.

Interpretation
This case of transfusion-associated vCJD infection, identified ante-mortem,
is the third instance from a group of 23 known recipients who survived at
least 5 years after receiving a transfusion from donors who subsequently
developed vCJD. The risk to the remaining recipients of such tranfusions is
probably high, and these patients should be offered specialist follow-up and
investigation. Tonsil biopsy will allow early and pre-symptomatic diagnosis
in other iatrogenically exposed individuals at high risk, as in those with
primary infection with bovine spongiform encephalopathy prions.

Affiliations

a. National Prion Clinic, National Hospital for Neurology and Neurosurgery,
Queen Square, London WC1N 3BG, UK
b. MRC Prion Unit and Department of Neurodegenerative Disease, Institute of
Neurology, University College London, London, UK
c. National Blood Service, London, UK

Correspondence to: Prof John Collinge



http://www.thelancet.com/journals/lancet/article/PIIS0140673606698358/abstract





TSS

#################### https://lists.aegee.org/bse-l.html
####################
 

Kathy

Well-known member
Link: http://www.sciencedaily.com/releases/2006/09/060925163456.htm

Quote:
Project Bioshield: Researchers To Develop Anti-Radiation Treatments

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has issued five awards totaling $4 million to fund the development of products that eliminate radioactive materials from the human body following radiological or nuclear exposure. The awards, which were granted under Project Bioshield authorities, complement NIAID's other medical countermeasure efforts to create safe and effective products of this type.

"These new grants will help identify new drug candidates that could be acquired by the strategic national stockpile of medical countermeasures, which is available to the public after a terrorist or nuclear attack or accidental radioactive exposure," says NIAID Director Anthony S. Fauci, M.D.

In the event of an attack by a nuclear explosive device or radiological "dirty bomb," individuals potentially could inhale, ingest or absorb through their skin radioactive atoms called radionuclides. Depending on the type of radionuclide that a person is exposed to, the particles may be excreted from the body or enter bones, organs or other tissues, which could have significant adverse health consequences. Through an initiative announced in 2005, NIAID already is working to speed the development of a series of products that can bind (chelate) internally with the radionuclides and eliminate (decorporate) them from the body. Radionuclide decorporation products currently are available in the strategic national stockpile, but NIAID is focusing on expanding the product pool, creating new treatments capable of eliminating a wider range of radionuclides, developing products that can eliminate radioactive material faster and in greater amounts; and developing products in formulations that could be distributed more easily in a mass casualty situation.

NIAID has awarded five grants totaling up to $4 million to fund work for a period of 18 months. The following principal investigators and universities are the recipients of the grants:

* Raymond J. Bergeron, Ph.D., University of Florida, Gainesville, $1.0 million

* Tatiana G. Levitskaia, Ph.D., Pacific Northwest National Laboratory, Richland, WA, $725,000

* Scott C. Miller, Ph.D., University of Utah School of Medicine, Salt Lake City, $675,000

* Kenneth N. Raymond, Ph.D., University of California/Lawrence Berkeley National Laboratory, Berkeley, CA, $998,325

* Charles Timchalk, Ph.D., Pacific Northwest National Laboratory, Richland, WA, $599,747

"The goal of this new program is to accelerate the development of previously identified, promising compounds into effective products that could be licensed for use," says program officer Bert Maidment, Ph.D., associate director of product development in NIAID's Division of Allergy, Immunology and Transplantation.

NIAID issued the grants under authority provided by Project Bioshield, which was signed into law in 2004. Its enactment provided federal agencies with new tools to speed research on medical countermeasures to protect Americans against chemical, biological, radiological or nuclear attack.

Does "attack" include contamination caused by the activities of your own government, Department of Defence, and corporations.

While this may seem a legitamate concern; there are more profound motivations behind the develoment of these radionuclide chelating agents. Any country with nuclear development(s), uranium mining, or those against which "depleted uranium" bombs were used (DU bombs are commonly referred to as dirty bombs), should pay close attention to the development of these chelating agents.

The Departments of Energy and Defence, with the help of the Atomic Energy Commissions, have effectively contaminated the planet. I certainly don't just blame the USA, many other countries have been involved with this scenario. Canada has uranium mining operations and nuclear power (in the East - where they can keep it). Not to mention that we have allowed the British to control the "Suffield Base" in southern Alberta for development of biological and radiological weapons and counter-measures.

It is interesting to note what the doctors given "Project Biosheild" funding have been working on in the past;

Dr. Kenneth Raymond - anthrax, Fe(III)-templated Gd(III) self-assemblies, iron chelators

Dr. Scott Miller - radionuclide contamination, including experiments with beagles, and inhalation of Plutonium by workers

Dr. TG Levitskaia - fluoride, metal ion complexes

Dr. Raymond J. Bergeron - iron overload, chelator design (iron chelation from specific organs)

Dr. C. Timchalk - identification of biomarkers in blood, saliva and urine for Organophosphates, Lead and other heavy metals.

http://www.pnl.gov/biology/highlights/2006102006_a.stm

Charles Timchalk and his team were granted $599,747 to create new forms of SAMMS - self-assembled monolayers on mesoporous supports - that could capture and naturally remove radionuclides from the body. Earlier SAMMS research showed that chelating agents can be attached to mesoporous materials and engineered to latch onto specific radionuclides. Chelating agents can deactivate radionuclides by forming bonds with their ions. the NIAD project will adapt SAMMS technology for radionuclide decorporation in humans. If the team is successful, the next step would be to move the results toward FDA (Foodand Drug Administration) approval. Commercially, this versatile technology is used to remove mercury contaminants from process water and smokestack emissions. Timchalk's team includes co-principal investigator Wassana Yantasee and key investigators Glenn Fryxell and Shane Addleman."

Treatment of humans will take not be limited to those already contaminated (if you can find any); but, as a propholactic food additive which will be incorporated without anyone knowing why.

If it can be used to treat water, then they need to adapt the technology (which will be extremely difficult, I would think) to cleaning blood and blood products (without damaging other components).

What about treatment of animals of husbandary, ie: cattle, pigs, sheep etc.

As for treatment of smokestack emissions, I don't believe we have this process here; and even if we did, they'd actually have to turn on their scrubbers for them to work. The thing about night time, is we can't see the color of the emissions from the stacks (coal generator station); but, we can certainly see more crap floating in the air. Nothing like a quick call to Environment to get those scrubbers turned back on (for a while).
 

flounder

Well-known member
Kathy said:
Link:

but, we can certainly see more crap floating in the air.

.



kathy, the only crap i see floating in the air are your hijacking of my postings that have nothing at all to do with the topic. and you seem to be full of it. your postings are really amusing :lol: :lol: :lol:
 

Kathy

Well-known member
You're the amuzing one, Dr. Flounder.

It is too bad that you will not acknowledge metal contamination of the prion protein, and the contamination of the brain with radionuclides. They may not be attached to the prion protein directly, but they are causing destuction in the brain which various proteins respond to.

In time we will know the truth. In the meantime, it is almost criminal that you refuse to look at the use of chelator compounds in the treatment of cjd or vcjd.

I haven't hijacked your threads... I am expressing my opinion on the subject which you refuse to research. Freedom of speach and assembly.

Thankfully, real doctors that I have been speaking with are alot more open minded than you. This is why I haven't been on the board much lately.

The decorporation of insoluble radionuclides is a challenge.
 
Top